Arcadia Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.5M
- Price
- $0.67
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.95%
- Volume
- 448.8K
Quote data as of 6:11 AM ET
About
Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products. Additionally, it is actively engaged in agricultural research and development, with a particular focus on improving wheat crops. The aim of these innovations is to enhance farmers' economic stability by boosting crop performance in the field, increasing their value for food and wellness applications, and expanding their potential for industrial uses. Established in 2002, the company's main office is located in Davis, California.
Quick stats
Shares outstanding2.2M
Computed float2.0M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorBasic Materials
IndustryAgricultural Inputs
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001469443
Websitehttps://www.arcadiabio.com
AI Summary
AI-generated26d agostandardbearishofferingArcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds.
The deal involved the sale of 3,883,496 shares of common stock (or pre-funded warrants) at $1.03 per share, along with Series A-1 and A-2 preferred investment options to purchase an additional 3,883,496 shares each at an exercise price of $0.91.
The offering was priced at-the-market under Nasdaq rules, with H.C. Wainwright acting as exclusive placement agent. Proceeds will be used for working capital and general corporate purposes.
Red flags
- Significant dilution: issuance of ~3.9M shares plus ~7.8M preferred options
- Use of proceeds is 'working capital and general corporate purposes' rather than specific operational milestones